Hepatitis C virus treatment is increasingly being offered in primary care because medications now require less frequent monitoring and have fewer adverse effects.
Health care spending avoided by increased hepatitis C treatment could more than offset direct spending on increased treatment, according to a new report from the Congressional Budget Office (CBO). A ...
Figure 1. The direct-acting antiviral targets in the hepatitis C virus replication cycle. NS3/4A protease inhibitors target the NS3/4A protease enzyme which is needed for the virus to develop the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results